UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): May 10, 2016

 

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
California
(State or Other Jurisdiction of Incorporation)

 

  333-198073   02-0692322  
  (Commission File Number)   (IRS Employer Identification No.)  

 

12744 San Fernando Road, Suite 400
Sylmar, California 91342
(Address of Principal Executive Offices)
 
(818) 833-5000
(Registrant's Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 

 

 

ITEM 5.07 Submission of Matters to a Vote of Security Holders. 

 

On May 10, 2016 Second Sight Medical Products Inc. ("Second Sight" or "Company") held its annual meeting of stockholders in Valencia, California. At the annual meeting, there were 36,019,086 shares of Second Sight's common stock entitled to vote, and 30,161,225 shares of Second Sight's common stock (83.74%) were represented at the meeting in person or by proxy. The following are the voting results on each matter submitted to the stockholders of Second Sight at the annual meeting of stockholders. The proposals acted upon by the stockholders are described in detail in Second Sight's Proxy Statement which was filed with the Securities and Exchange Commission on April 15, 2016.

  

Proposal 1: The stockholders elected each of the six director nominees to the Board of Directors of the Company to serve until the 2017 Annual Meeting of Stockholders and until his successor has been duly elected and qualifies, as follows:

 

   Votes For   Votes Against   Abstentions   Broker Non-Votes 
Will McGuire   24,581,759    39,470    65,422    5,474,574 
Robert J. Greenberg   24,586,063    39,941    60,647    5,474,574 
William J. Link   24,494,961    80,146    111,544    5,474,574 
Aaron Mendelsohn   24,456,191    72,619    157,841    5,474,574 
Matthew Pfeffer   24,556,171    63,904    66,576    5,474,574 
Gregg Williams   24,508,812    67,368    110,471    5,474,574 

 

Proposal 2: The stockholders approved amendments to the 2011 Equity Incentive Plan (“Plan”) to (i) increase the maximum number of shares of common stock that may be issued under the Plan by 1,500,000 shares – from 6,000,000 shares to 7,500,000 shares; (ii) add the ability for the Company to grant restricted stock units (“RSUs”) under the Plan; and (iii) permit the Company, at any time in its discretion, to reprice or exchange outstanding options under the Plan, as follows:

 

   Votes For   Votes Against   Abstentions   Broker Non-Votes 
    23,343,977    894,168    448,506    5,474,574 

 

Proposal 3: The stockholders ratified the appointment of Gumbiner Savett Inc. as Second Sight’s independent registered public accounting firm for the year ending December 31, 2016, as follows:

 

   Votes For   Votes Against   Abstentions   Broker Non-Votes 
    29,931,297    71,935    157,993    0 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 10, 2016

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

 

 /s/ Thomas B. Miller  
By: Thomas B. Miller  
Chief Financial Officer